ENvue Medical, Inc.
Close on Oct 19, 2026
- Market cap
- $3.08M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2022 Ended Mar 31, 2022 | May 17, 2022 | Before market open | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 17, 2021 | Before market open | – | – | – |
| Q3 FY2020 Ended Sep 30, 2020 | Nov 17, 2020 | After market close | – | – | – |
Press releases
Announcements ENvue Medical filed with the SEC
Medical, Inc. Announces 1-for-12 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Inc. Announces Name and Ticker Symbol Change to ENvue Medical, Inc. and ‘FEED’
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Feeding Tube Placement System Identified as Core Growth Platform
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
NanoVibronix Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
TEXAS – June 4, 2025 – NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a
Executive or director change · Other events · EX-99.1 to Form 8-K
Announces Pricing of $10 Million Public Offering of Preferred Stock and Warrants
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Independent Study of the NanoVibronix UroShield ® Device Published in the Australian and New Zealand Continence Journal
Regulation FD disclosure · EX-99.1 to Form 8-K
Stock Will Begin Trading on Split-Adjusted Basis on March 14, 2025
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
MEDICAL HOLDINGS, CORP. (FORMERLY ENVIZION HOLDINGS CORP.)
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Interim Consolidated Statements of Operations
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
Announces Completion of Pilot Phase of Clinical Study of UroShield® at the University of Michigan
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
N.Y., April 9, 2024 (Business Wire) -- NanoVibronix, Inc ., (NASDAQ: NAOV)( “ NanoVibronix”),
Regulation FD disclosure · EX-99.1 to Form 8-K
Signs Agreement for Research and Development of Next Generation PainShield and UroShield
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Agreement for Clinical Study of UroShield at the University of Michigan
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
UroShield Products Available on NHS Drug Tariff Effective November 1
Regulation FD disclosure · EX-99.1 to Form 8-K
Gains Approval for Inclusion of UroShield Products in
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Cites Positive Results from Independent Testing of UroShield
Regulation FD disclosure · EX-99.1 to Form 8-K
Responds to CMS’ Determination for PainShield
Regulation FD disclosure · EX-99.1 to Form 8-K
Applies for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
Regulation FD disclosure · EX-99.1 to Form 8-K
Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Distribution Agreement with Sports Medicine Supplier Mio-Guard
Regulation FD disclosure · EX-99.1 to Form 8-K
N.Y., May 18, 2023 (Business Wire) — NanoVibronix, Inc ., (NASDAQ: NAOV), a medical
Regulation FD disclosure · EX-99.1 to Form 8-K